Select Language:
US-based heart valve manufacturer is highlighting its latest PASCAL Precision Transcatheter Valve Repair system at the upcoming China International Import Expo.
“This year, we’re thrilled to introduce the PASCAL Precision system for treating mitral and tricuspid regurgitation, making its debut at this event after its launch in Hong Kong,” said Ben Cheong, senior vice president and general manager for Greater China.
The PASCAL Precision system represents the company’s initial step into the Chinese market for transcatheter therapies targeting mitral and tricuspid valves, broadening its portfolio beyond the well-established transcatheter aortic valve replacement options.
In China, where approximately 25 million people suffer from heart valve diseases, many are impacted by mitral or tricuspid regurgitation. Without prompt treatment, these patients face a significantly higher risk of death, emphasizing the importance of early diagnosis and intervention, Cheong explained.
Several products introduced at previous editions of the expo have already made their way into clinical practice. The SAPIEN 3 Transcatheter Aortic Valve System, first showcased in 2020, is now in use at nearly 200 hospitals across China. The INSPIRIS RESILIA aortic valve, also revealed at the 2020 event, has successfully treated over 4,000 patients and continues to be supported by local post-market studies.
“Local data is incredibly valuable for physicians,” Cheong added. “We’re excited to share that we’ll be releasing early results from our ongoing post-market study of the INSPIRIS RESILIA in the coming months.”
Research efforts are ongoing at prominent institutions such as Fuwai Hospital of the Chinese Academy of Medical Sciences and Zhongshan Hospital affiliated with Fudan University, assessing the performance of INSPIRIS RESILIA among Chinese patients and investigating its applications for younger individuals with aortic stenosis.
To boost clinical capabilities, the company has trained over 40,000 Chinese healthcare professionals through its Surgical Academy centers and the SAPIEN 3 Teaching Center of Excellence.
Partnerships with China’s Sinopharm Group and Shanghai Pharmaceuticals have also been strengthened to improve hospital access and streamline distribution channels domestically.
“Having local partners is crucial, especially to ensure the efficient delivery of our products to hospitals,” Cheong emphasized. “We’re committed to exploring innovative solutions to better serve our patients and healthcare facilities.”
Looking ahead, the company plans to accelerate its product pipeline, with the PASCAL Precision system expected to launch next year and the following. Additionally, a new SAPIEN 3 Ultra RESILIA product is in development, along with other innovations.
ChatGPT
Perplexity
Gemini AI
Grok AI
